Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 33745 - coated knee femur prosthesis - the madison ha coated ps femoral component is made of cobalt chromium alloy and has a hydroxyapatite coating. it has a postero-stabilised design and articulates with either a fixed bearing or mobile bearing platform madison tibial base/insert and is for cementless use. the madison ha coated ps femoral component is a femoral component of the madison total knee replacement system and is intended for cementless use to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 32831 - uncoated knee femur prosthesis - the madison cemented ps femoral component is made of cobalt chromium alloy and has a postero-stabilised design. it is for cemented use and it articulates with either a fixed bearing or mobile bearing platform madison tibial base/insert. the madison cemented ps femoral component is a femoral component of the madison total knee replacement system and is intended for cemented use to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 33745 - coated knee femur prosthesis - the madison ha coated cr femoral component is made of cobalt chromium alloy and has a hydroxyapatite coating. it has a cruciate retaining design and articulates with either a fixed bearing or mobile bearing platform madison tibial base/insert and is for cementless use. the madison ha coated cr femoral component is a femoral component of the madison total knee replacement system and is intended for cementless use to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 32831 - uncoated knee femur prosthesis - the madison cemented cr femur is made of cobalt chromium alloy and has a cruciate retaining design. it articulates with either a fixed bearing or mobile bearing platform madison tibial base/insert and is for cemented use. the madison cemented cr femur is a femoral component of the madison total knee replacement system and is intended for cemented use to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 34199 - polyethylene patella prosthesis - the madison cemented patella is a patella resurfacing implant made from uhmwpe. it has three pegs and is for cemented use only. the madison patella is the patella component of the madison total knee replacement system and is intended to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 33580 - uncoated knee tibia prosthesis, polyethylene - the madison posterior stabilising insert is a uhmwpe insert with 4 degrees of posterior slope. it attaches to a madison tibial base and articulates with a madison (posterior stabilising) femoral component. the madison posterior stabilising insert is a bearing component of the madison total knee replacement system and is intended to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

kico knee innovation company pty ltd - 33580 - uncoated knee tibia prosthesis, polyethylene - the madison cruciate retaining insert is a fixed or mobile bearing uhmwpe insert with 4 degrees of posterior slope. it attaches to a madison tibial base and articulates with a madison (cruciate retaining) femoral component. the madison cruciate retaining insert is a bearing component of the madison total knee replacement system and is intended to replace the knee joint. the main indications are as follows: - degenerative osteoarthritis or post traumatic arthrosis, in patients whose age, weight, and level of activity are compatible with a satisfactory long term result - rheumatoid polyarthritis - revision of unicompartmental arthroplasty procedure, if bone mass and ligament stability allow - failed osteotomy

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

allergan, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e) - pancrelipase lipase 10440 [usp'u] -       viokace  tablets, in combination with a proton pump inhibitor,  is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.       none.       risk summary  published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase.       the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.       ri

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

allergan, inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 5 mg - norco is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use : because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve norco for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia norco is contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to hydrocodone or acetaminophen (e.g., anaphylaxis) [see warnings , adverse reactions ] norco contains hydrocodone, a schedule ii controlled substance. norco co

Australia - Inggeris - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bell laboratories, inc. - bromadiolone - bait - bromadiolone coumarin active 0.05 g/kg - vertebrate poison - building | commercial/industrial premises | domestic and/or public area | farm and/or animal housing | food processing and/or pr - mouse - mus spp. | rat